Benzinga | Jun 28, 2021 07:57AM EDT

Barclays Maintains Overweight on Intellia Therapeutics, Raises Price Target to $134

Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and raises the price target from $88 to $134.